Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

Enrique Rozengurt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7838-9170; OpenAlex author ID A5077935609. Sources: OpenAlex.

Their work

Papers
28 (first author 3, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 28

  1. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. Co-author DOI 10.1038/s41392-025-02499-y↗
  2. Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream. Last author DOI 10.1158/1940-6207.capr-26-0197↗
  3. Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-24-0785↗
  4. Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16081593↗
  5. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Co-author DOI 10.1038/s41598-023-43498-9↗
  6. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy. Last author DOI 10.1158/1535-7163.mct-21-0964↗
  7. Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. First author DOI 10.1007/s10555-021-09977-z↗
  8. Obesity and Pancreatic Cancer: Insight into Mechanisms. First author DOI 10.3390/cancers13205067↗
  9. Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Co-author DOI 10.3390/cancers13205126↗
  10. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. First author DOI 10.1016/j.semcancer.2017.10.007↗
  11. Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. Co-author DOI 10.1152/ajpgi.00170.2019↗
  12. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pa… Last author DOI 10.1371/journal.pone.0216603↗
  13. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. Co-author DOI 10.3748/wjg.v25.i15.1797↗
  14. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Co-author DOI 10.1038/s41392-017-0005-2↗
  15. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Last author DOI 10.1038/s41598-018-24337-8↗
  16. Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. Co-author DOI 10.1186/s12885-018-4713-y↗
  17. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Co-author DOI 10.1016/j.surg.2016.12.037↗
  18. Pancreatic cancer actionable genes in precision medicine and personalized surgery. Co-author DOI 10.1016/j.surge.2016.05.002↗
  19. Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. Last author DOI 10.1158/1541-7786.mcr-17-0023↗
  20. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  21. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/1566524016666151222145551↗
  22. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Last author DOI 10.1158/1535-7163.mct-14-0669↗
  23. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Ca… Last author DOI 10.1371/journal.pone.0114573↗
  24. Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cell… Co-author DOI 10.3389/fphys.2014.00357↗
  25. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Last author DOI 10.1016/j.bbrc.2012.11.010↗
  26. Metformin inhibits the growth of human pancreatic cancer xenografts. Last author DOI 10.1097/mpa.0b013e31827aec40↗
  27. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0057289↗
  28. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. Co-author DOI 10.1002/jcp.22421↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guido Eibl · 20 shared papers, 2013–2026 · strength 3.92
  2. James W. Sinnett‐Smith · 16 shared papers, 2011–2025 · strength 1.50
  3. Oscar Joe Hines · 7 shared papers, 2017–2026 · strength 1.23
  4. Hui-Hua Chang · 7 shared papers, 2017–2024 · strength 0.68
  5. Yaroslav Teper · 3 shared papers, 2022–2025 · strength 0.63
  6. Xiaoying Sun · 2 shared papers, 2023–2025 · strength 0.45
  7. Aurelia Lugea · 3 shared papers, 2017–2024 · strength 0.43
  8. Richard T. Waldron · 3 shared papers, 2017–2024 · strength 0.43
  9. Stephen Jacob Pandol · 3 shared papers, 2017–2024 · strength 0.43
  10. Hao Fang · 3 shared papers, 2017–2019 · strength 0.25
  11. David W. Dawson · 3 shared papers, 2017–2018 · strength 0.20
  12. Qinhong Xu · 2 shared papers, 2017–2019 · strength 0.18
  13. Linda Ye · 1 shared paper, 2023 · strength 0.18
  14. Heloisa Prado Soares · 3 shared papers, 2013–2015 · strength 0.15
  15. Andrea Schmidt · 2 shared papers, 2017–2018 · strength 0.15
  16. Krisztina Kisfalvi · 3 shared papers, 2013 · strength 0.15
  17. John J. Nemunaitis · 2 shared papers, 2016–2017 · strength 0.14
  18. Francis Charles Brunicardi · 2 shared papers, 2016–2017 · strength 0.14
  19. Ming Ming · 2 shared papers, 2014–2015 · strength 0.10
  20. Tien Sy Dong · 1 shared paper, 2019 · strength 0.10
  21. Juehua Yu · 1 shared paper, 2017 · strength 0.08
  22. Mu Xu · 1 shared paper, 2018 · strength 0.08
  23. Jonathan C. King · 1 shared paper, 2018 · strength 0.08
  24. Yinglan Zhao · 1 shared paper, 2017 · strength 0.08
  25. James X. Wu · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.